Clinical Trials Logo

Alzheimer Disease, Late Onset clinical trials

View clinical trials related to Alzheimer Disease, Late Onset.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05183516 Not yet recruiting - Clinical trials for Alzheimer Disease, Late Onset

Tdap and Biomarkers of Alzheimer's Disease

Start date: May 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Recently, the Tdap (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) vaccination was added to the list of immunizations associated with lower incidence of dementia. Plasma-based biomarkers for AD are a welcome alternative to expensive and invasive testing for Alzheimer's; these biomarkers include assessment of amyloid and tau and neurofilament light protein that assesses non-specific neurodegeneration. The investigators will test for these biomarkers, as well as some immune parameters, administer Tdap then repeat the blood tests in six months.